• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:32:24 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TARA alert in real time by email
    SC 13G/A 1 rocksprings-tara123120a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    Protara Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    74365U107

    (CUSIP Number)

     

     

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  74365U107
     SCHEDULE 13G/A
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital Management LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    643,200
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    643,200
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    643,200
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.74%
    12
    TYPE OF REPORTING PERSON
     
    IA

     

     


     

    CUSIP No.  74365U107
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    643,200
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    643,200
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    643,200
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.74%
    12
    TYPE OF REPORTING PERSON
     
    OO; HC

     

     


     

    CUSIP No.  74365U107
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital Master Fund LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    625,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    625,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    625,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.57%
    12
    TYPE OF REPORTING PERSON
     
    PN

     

     
     

     

    CUSIP No.  74365U107
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Protara Therapeutics, Inc. (the “Issuer”)

    (b) Address of Issuer’s Principal Executive Offices

    345 Park Avenue South, Third Floor, New York, NY 10010

     

    Item 2.(a) Name of Person Filing

    This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

    i. Rock Springs Capital Management LP (“RSCM”);

    ii. Rock Springs Capital LLC (“RSC”); and

    iii. Rock Springs Capital Master Fund LP (“Master Fund”).

    This Statement relates to Shares (as defined herein) held directly by each of the Master Fund, which is a Cayman Islands exempted limited partnership, and Four Pines Master Fund LP (“Four Pines”), which is a Cayman Islands exempted limited partnership, and indirectly held by RSCM, a Delaware limited partnership, and RSC, a Delaware limited liability company. RSCM serves as the investment manager to each of the Master Fund and Four Pines. RSC is the general partner of RSCM.

    (b) Address of Principal Business Office, or, if none, Residence

    Rock Springs Capital Management LP and Rock Springs Capital LLC 

    650 South Exeter St., Suite 1070

    Baltimore, MD 21202

    Rock Springs Capital Master Fund LP

    c/o Walkers Corporate Limited

    Cayman Corporate Centre

    27 Hospital Road

    George Town, Grand Cayman, KY1-9008, Cayman Islands

     

    (c) Citizenship

    Rock Springs Capital Management LP - Delaware

    Rock Springs Capital LLC - Delaware

    Rock Springs Capital Master Fund LP - Cayman Islands

     (d) Title of Class of Securities

    Common Stock, par value $0.001 per share (the “Shares”)

     (e) CUSIP No.:

    74365U107

     
     

     

    CUSIP No.  74365U107
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not Applicable.

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

     
     

     

    CUSIP No. 74365U107
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    As of the date of this filing, each of RSCM and RSC may be deemed to be the indirect beneficial owners of 643,200 Shares, which amount includes 625,000 Shares directly beneficially owned by the Master Fund, and 18,200 Shares directly beneficially owned by Four Pines. The percent of class is determined by dividing the number of Shares beneficially owned by the Reporting Persons by 11,211,840, the amount of Common Stock outstanding as reported on the Issuer’s 10-Q filed on November 12, 2020.

    (a) Amount beneficially owned:

    Rock Springs Capital Management LP: 643,200

    Rock Springs Capital LLC: 643,200

    Rock Springs Capital Master Fund LP: 625,000

     

    (b) Percent of class:

    Rock Springs Capital Management LP: 5.74%

    Rock Springs Capital LLC: 5.74%

    Rock Springs Capital Master Fund LP: 5.57%

     

    (c) Number of shares as to which the person has:

     

    (i) Sole power to vote or to direct the vote:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    (ii) Shared power to vote or to direct the vote:

    Rock Springs Capital Management LP: 643,200

    Rock Springs Capital LLC: 643,200

    Rock Springs Capital Master Fund LP: 625,000

     

    (iii) Sole power to dispose or to direct the disposition of:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

    Rock Springs Capital Master Fund LP: 0

     

    (iv) Shared power to dispose or to direct the disposition of:

    Rock Springs Capital Management LP: 643,200

    Rock Springs Capital LLC: 643,200

    Rock Springs Capital Master Fund LP: 625,000

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not applicable.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    See disclosure in Items 2 and 4 hereof. Certain funds listed in Item 2(a) are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares covered by this Statement that may be deemed to be beneficially owned by the Reporting Persons.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Please see response to Item 2.

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     
     
    CUSIP No.  74365U107
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 16, 2021

     

     

     

    Rock Springs Capital Management LP

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

      Rock Springs Capital LLC
           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

      Rock Springs Capital Master Fund LP
     

    By: Rock Springs Capital Management LP, Investment Manager

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

     

     
     
    CUSIP No.  74365U107
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

     

    JOINT FILING AGREEMENT

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Date: February 16, 2021

     

     

     

    Rock Springs Capital Management LP

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

      Rock Springs Capital LLC
           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

      Rock Springs Capital Master Fund LP
     

    By: Rock Springs Capital Management LP, Investment Manager

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

     

     

     

     

     

     

    Get the next $TARA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TARA

    DatePrice TargetRatingAnalyst
    1/7/2026$24.00Overweight
    Piper Sandler
    4/16/2025$12.00Sector Outperform
    Scotiabank
    3/14/2025Overweight
    Cantor Fitzgerald
    7/10/2023$22.00Buy
    Guggenheim
    11/8/2021$32.00 → $34.00Outperform
    Oppenheimer
    More analyst ratings

    $TARA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Protara Therapeutics with a new price target

    Piper Sandler initiated coverage of Protara Therapeutics with a rating of Overweight and set a new price target of $24.00

    1/7/26 9:14:32 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scotiabank initiated coverage on Protara Therapeutics with a new price target

    Scotiabank initiated coverage of Protara Therapeutics with a rating of Sector Outperform and set a new price target of $12.00

    4/16/25 8:13:38 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Protara Therapeutics

    Cantor Fitzgerald initiated coverage of Protara Therapeutics with a rating of Overweight

    3/14/25 7:42:48 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to one newly-hired employee. The Compensation Committee of Protara's Board of Directors approved an aggregate of 10,200 stock option awards and 5,100 RSU awards to one new employee from the Inducement Plan, as inducements material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on February 2, 20

    2/2/26 4:05:25 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium

    NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated interim data from the cohort of BCG-Unresponsive non-muscle invasive bladder cancer (NMIBC) patients in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 will be featured at the upcoming American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place from February 26, 2026 to February 28, 2026 in San Francisco. The poster presentation will include updated safety and efficacy data from approximately 25 six-month evaluable BCG-Unresponsive N

    1/22/26 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

    On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H 2026 Dosed first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support and expect to report interim results in 2H 2026 Recently completed approximately $86 million public offering extending cash runway into 2028 NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of canc

    1/12/26 7:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    SEC Filings

    View All

    SEC Form 424B7 filed by Protara Therapeutics Inc.

    424B7 - Protara Therapeutics, Inc. (0001359931) (Filer)

    2/2/26 4:30:21 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Protara Therapeutics, Inc. (0001359931) (Filer)

    12/15/25 4:15:24 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B7 filed by Protara Therapeutics Inc.

    424B7 - Protara Therapeutics, Inc. (0001359931) (Filer)

    12/9/25 4:16:14 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Fabbio Patrick covered exercise/tax liability with 3,261 shares, decreasing direct ownership by 5% to 64,115 units (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    1/27/26 4:10:13 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    VP, Controller Fry Hannah covered exercise/tax liability with 1,457 shares, decreasing direct ownership by 3% to 42,723 units (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    1/27/26 4:10:15 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO and President Shefferman Jesse covered exercise/tax liability with 8,732 shares, decreasing direct ownership by 0.85% to 1,021,832 units (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    1/27/26 4:10:07 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Levy Richard S bought $63,800 worth of shares (20,000 units at $3.19), increasing direct ownership by 65% to 51,000 units (SEC Form 4)

    4/A - Protara Therapeutics, Inc. (0001359931) (Issuer)

    5/19/25 4:10:10 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Levy Richard S bought $63,800 worth of shares (20,000 units at $3.19), increasing direct ownership by 65% to 51,000 units (SEC Form 4)

    4 - Protara Therapeutics, Inc. (0001359931) (Issuer)

    5/16/25 4:05:07 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Financials

    Live finance-specific insights

    View All

    Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients

    TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patientsTARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Naïve patientsFavorable safety and tolerability profile observed with no Grade 3 or greater treatment-related adverse events reportedCompany obtained written feedback from FDA on registrational path forward for TARA-002 in BCG-Naïve patientsCompany remains on track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in the registrational cohort of the ADVANCED-2 trial in Q1 2026 Company expects to complete enrollment of the BCG-Unre

    12/3/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025

    NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a conference call and live webcast at 8:30 am ET on Wednesday, December 3, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC). The data will be featured during a poster session at the 26th Annual Meeting of the Society of Urologic Oncology (SUO). The Company will also provide an update on feedback from the U.S. Food and Drug Administrat

    12/1/25 4:15:00 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

    80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical successClinical success achieved with one or two doses of TARA-002 in 88% of patients TARA-002 demonstrated favorable safety and tolerability profile with no serious adverse events reportedCompany to host conference call and webcast featuring Key Opinion Leader Dr. Jesse Jones at 8:30 a.m. ET NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced positive interim results from its ongoing Phase 2 open-label S

    11/19/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Leadership Updates

    Live Leadership Updates

    View All

    Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

    Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical conference in 1Q 2026 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support on track for 3Q 2025   On track to provide an interim update from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients in 4Q 2025 Cash, cash equivalents and investments of approximately $146 million as of June 30, 2025, expected to support planned operations into mid-2027 NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage com

    8/11/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Announces Addition to the Russell 3000® Index

    NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has been added as a member of the broad-market Russell 3000® Index as part of the annual reconstitution, effective at the open of U.S. equity markets today, June 30, 2025. "Protara's inclusion in the Russell 3000® Index is a reflection of the progress that we have made executing across our pipeline, including the advancement of clinical trials for TARA-002 in non-muscle invasive bladder cancer and lymphatic malformations and the development of our IV Choline Chlorid

    6/30/25 8:00:00 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

    NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of William "Bill" Conkling as Chief Commercial Officer. He brings more than two decades of experience developing and commercializing novel cancer and rare disease therapeutics to Protara. "It is a pleasure to welcome Bill, a deeply experienced and proven commercial leader," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. "With an impressive track record building commercial organizations and successfully launching oncology and rare disease prod

    6/2/25 4:04:01 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Protara Therapeutics Inc.

    SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

    12/17/24 4:02:03 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Protara Therapeutics Inc.

    SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

    11/18/24 6:01:42 AM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Protara Therapeutics Inc.

    SC 13G - Protara Therapeutics, Inc. (0001359931) (Subject)

    11/14/24 1:00:40 PM ET
    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care